Island Pharmaceuticals Ltd · ASX:ILA
Island Pharmaceuticals — Investor Presentation (February 2024)
24 slides from Island Pharmaceuticals's investor presentation, Feb 6, 2024
Slide 1: Solving Urgent Viral Disease Threats
SOLVING URGENT VIRAL DISEASE THREATS (ASX: ILA) | February 2024 ISLAND PHARMACEUTICALS 1 FEBRUARY 2024
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Island Pharmaceuticals Limited (ABN 641 183 842) (Company or Future performance Island Pharmaceuticals). This presentation contains certain "forward-looking statements". The words "expect", "anticipate", Not an offer or financial product advice "esti
Slide 3: Island Pharmaceuticals is a drug repurposing company
Island Pharmaceuticals (ASX: ILA) is a drug repurposing company, focused on the rapid development of antiviral therapeutics for infectious diseases ISLAND PHARMACEUTICALS 3 FEBRUARY 2024
Slide 4: Island at a Glance
ISLAND AT A GLANCE Dengue infects up to Major market Positive results in 400m per year* potential aggressive models Now endemic in more than 100 ISLA-101 has potential to address Of animal and human cellular countries, as well as previously mosquito-borne diseases, which are models of dengue fever a
Slide 5: About half of the world's population is now at risk of dengue
“About half of the world's population is now at risk of dengue with an estimated 100–400 million infections occurring each year” World Health Organisation, 17 March 2023 ISLAND PHARMACEUTICALS 5 FEBRUARY 2024
Slide 6: Dengue is a widespread issue
DENGUE IS A WIDESPREAD ISSUE Dengue outbreaks occurred in many countries of the world in the Americas, Africa, the Middle East, Asia, and the Pacific Islands HealthMap: recent reports of local or imported dengue cases https://www.healthmap.org/dengue/en - visited January 11, 2024 ISLAND PHARMACEUTIC
Slide 7: Dengue in 2050 – a global disease
DENGUE IN 2050 – A GLOBAL DISEASE Prediction based on projections of future temperatures, rainfall, and mosquito populations Europe USA Australia NASA Earth Observatory map by Lauren Dauphin based on data from Janey Messina, University of Oxford - https://earthobservatory.nasa.gov/features/disease-v
Slide 8: Dengue fever will become a major threat
“Dengue fever will become a major threat in the southern US, southern Europe and new parts of Africa this decade” World Health Organisation, 6 October 2023 ISLAND PHARMACEUTICALS 8 FEBRUARY 2024
Slide 9: Commercial Opportunity
COMMERCIAL OPPORTUNITY ISLA-101 has potential as both a prophylactic and therapeutic Travelers Military National Outbreaks The malaria market, expected Partnering with army (CRADA Millions of patients in Latin to reach US$1B by 20261, is in place) for Phase 2a clinical America offer potential for ex
Slide 10: Introducing ISLA-101
Introducing ISLA-101 ISLAND PHARMACEUTICALS 10 FEBRUARY 2024
Slide 11: ISLA-101 Broad Activity Evident
ISLA-101 BROAD ACTIVITY EVIDENT Demonstrated activity against flaviviruses (a subgroup of arboviruses) in multiple models of infection Dengue • In in-vitro models using fresh human cells, ISLA-101 has 1-4 demonstrated broad anti-viral activity • In animal models, ISLA-101 is protective in dengue fev
Slide 12: Prevents Animal Deaths from Lethal Dengue
PREVENTS ANIMAL DEATHS FROM LETHAL DENGUE ISLA-101 has also been shown to be protective in animal models of both dengue and Zika Virus. Survival curve showing protection from lethal dengue change by Increasing dose of ISLA101 (mouse model). Fraser et al. J. Infect. Dis 2014 ISLAND PHARMACEUTICALS 12
Slide 13: Recent ISLA-101 Progress
RECENT ISLA-101 PROGRESS Final cohort dosed in Single Ascending Dose Received human study research ethics committee Grant research approval to support commence Single announced for Ascending Dose ILA receives FDA study; first cohort the planned go-ahead for dosed PEACH study in ISLA-101 ILA submits
Slide 14: Single Ascending Dose Study – Key Activities
SINGLE ASCENDING DOSE STUDY – KEY ACTIVITIES Several workstreams are underway, providing support for commencing the Single Ascending Dose study Signed Finalized / Obtained First and Third cohort, Signed clinical Final SAD Material Clinical signed Human second then last site in Patient study data shi
Slide 15: Single Ascending Dose Study Protocol
SINGLE ASCENDING DOSE STUDY PROTOCOL The aim of the study is to ensure that increasing doses of ISLA-101 are safe and well tolerated, and that administered doses could safely achieve blood concentrations that are predicted to be effective against the dengue virus. Inclusion Exclusion Dosing • Doses
Slide 16: Study Partners
STUDY PARTNERS Scientia Clinical Research is an FDA Beyond is a leading Contract Research audited, early phase clinical trials Organisation (CRO) based in Brisbane, facility, with world-class clinical trial Australia, with a focus on product expertise and state of the art facilities. development and
Slide 17: ISLA-101 Development Milestones
ISLA-101 DEVELOPMENT MILESTONES • Island expects to have final data from the Single Ascending Dose study for ISLA-101 in early CY2024 • The company plans to seek a meeting with the US FDA to discuss the study outcomes and strategies for how to maximise the data obtained from the PEACH* study • The P
Slide 18: Phase II Dengue (PEACH) Trial Study
PHASE II DENGUE (PEACH) TRIAL STUDY “PEACH" study- A Phase 2a, Randomized, Double blind, Placebo-controlled Study for the Prophylactic Examination of an Antiviral in a Dengue Challenge Model Phase II trial protocol Administer ISLA-101 daily Up to 4 cohorts/4 arms Inclusion Primary endpoint -3 0 20 2
Slide 19: Building Our Pipeline
BUILDING OUR PIPELINE • In addition to ISLA-101, Island is exploring the acquisition or in-licensing of new drug candidates • Specific screening and scoring criteria being applied, based in part on the following criteria: • small molecule program • anti-viral • eligible for a Priority Review Voucher
Slide 20: Board and Corporate Snapshot
BOARD AND CORPORATE SNAPSHOT Dr Paul MacLeman Dr David Foster Dr David Brookes Mr Albert Hansen Dr Anna Lavelle Corporate snapshot Executive Chairman Managing Director Non-Executive Director Non-Executive Director Non-Executive Director Key data points Dr Paul MacLeman brings Dr Foster has 25+ years
Slide 21: Other Key Team Members
OTHER KEY TEAM MEMBERS Bobbi Drais Nick McCoy Senior Regulatory Consultant Vice President Clinical Product Development Bobbi is a dynamic global leader with an impressive track record spanning Nick is an experienced clinical research professional with a demonstrated over 25 years in regulatory affai
Slide 22: Scientific Advisory
SCIENTIFIC ADVISORY SLIDE Dr Leigh Farrell Prof Stephen Thomas MD Dr Amy Patick Leigh has over 30 years’ experience in the Professor Stephen Thomas, MD has an international Amy Patick is a scientific consultant with deep biotechnology and pharmaceutical industry and is leadership role as Lead Princi
Slide 23: Upcoming Milestones
UPCOMING MILESTONES Completed H1 FY 2024 (Jul – Dec 2023; Completed) H2 FY 2024 (Jan – Jun 2024) Investigational New Drug • Key US and Australian patents • Dose final Single Ascending application for ISLA-101 PEACH granted for ISLA-101 Dose study subject study opens • Obtain HREC (i.e. IRB) approval
Slide 24: Contact
Contact David Foster Chief Executive Officer & Executive Director dfoster@islandpharmaceuticals.com islandpharmaceuticals.com @IslandPharma Island Pharmaceuticals ISLAND PHARMACEUTICALS 24 FEBRUARY 2024
Island Pharmaceuticals — Investor Presentation (February 2024) on 6ix